Formycon AGHAM:FYB 65 Pretax Margin % is -100.37% as of Dec. 2025. GuruFocus rates HAM:FYB with a GF Score™ of 65/100 and a GF Value™ of €36.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Formycon AG ranks worse than 60.36% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Formycon AG's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-35.61 Mil. Formycon AG's Revenue for the
six
months ended in Dec. 2025 was €35.48 Mil. Therefore, Formycon AG's pretax margin for the quarter that ended in Dec. 2025 was -100.37%.
The historical rank and industry rank for Formycon AG's Pretax Margin % or its related term are showing as below:
HAM:FYB'
s Pretax Margin % Range Over the Past 10 Years
Min: -207.04 Med: -13.15 Max: 101.77
Current: -203.47
HAM:FYB's Pretax Margin % is ranked worse than 60.36% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs HAM:FYB: -203.47
Formycon AG (HAM:FYB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Formycon AG Pretax Margin % Related Terms
Formycon AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Formycon AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:FYB vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Formycon AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Formycon AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (HAM:FYB) has a Pretax Margin % of -100.37% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #568 out of 941 companies in the Biotechnology industry, placing it in the top 60.4%.
Is Formycon AG's Pretax Margin % too high?
Formycon AG's current Pretax Margin % is -100.37%. Based on the distribution chart, Formycon AG ranks #568 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Formycon AG has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #568 out of 941 companies for Pretax Margin %. This places Formycon AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Formycon AG and its competitors. Formycon AG's current Pretax Margin % is -100.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (HAM:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €36.12, compared to a current price of €19.12 — trading 47.1% below its estimated fair value. The current Pretax Margin % is -100.37%. Formycon AG's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Formycon AG (HAM:FYB), the current Pretax Margin % is -100.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (HAM:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €19.12 is trading 47.1% below its estimated GF Value™ of €36.12.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for HAM:FYB:
Pretax Margin %: -100.37%
GF Value™: €36.12 vs. price of €19.12 (47.1% below fair value)
No single metric tells the full story. See the HAM:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score
Get the complete analysis for HAM:FYB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:FYB has been successfully added to your 
